Stimulant medication study for PTSD
Part of Mental health clinical trials.
This study tests whether a stimulant medication can help reduce PTSD symptoms. If you have PTSD and are generally healthy, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 65
- Body mass index (BMI) between 19 and 30
- Able to speak and read English
- No current or past stimulant or cocaine use disorder
- No current suicidal thoughts or attempts in the past 6 months
- No history of schizophrenia, schizoaffective disorder, or bipolar disorder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a study medicine that blocks the effects of cortisol (a stress hormone) to reduce PTSD symptoms in Veterans. It’s meant for people with ongoing PTSD symptoms and stable treatments, and it closely checks safety because the medicine can affect sleep, mood, and heart rhythm.
This study tests whether a combination of two medications (reboxetine and Ritalin) is more effective than dog-assisted therapy for reducing PTSD symptoms. Participation involves either taking the medications or attending dog therapy sessions.
This trial tests if a single infusion of allopregnanolone (a natural brain chemical) can help people with PTSD reduce fear responses and improve memory processing. It may offer a new way to treat PTSD by targeting how the brain stores traumatic memories.
This Phase 2 trial tests whether therapy assisted by MDMA can reduce symptoms of moderate to severe post-traumatic stress disorder (PTSD) in eligible veterans. It includes supervised therapy sessions and extra study visits with video recording to track changes over time.
This study tests whether MDMA (a drug that can help people feel safe and open during therapy) combined with talk therapy can reduce PTSD symptoms in active-duty service members, National Guard, and Reserve members. If you are struggling with PTSD that has lasted at least 6 months, this trial may offer a new treatment option.
This Phase 2 study tests whether MDMA combined with therapy that uses exposure (gradual confronting of trauma memories) can reduce PTSD symptoms. It may help people who meet PTSD criteria, can follow strict safety rules, and can complete medicine-session monitoring.
Hear when a new PTSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.